Michelle Wardzinski - Associate Director Biotech (@wardzi2michelle) 's Twitter Profile
Michelle Wardzinski - Associate Director Biotech

@wardzi2michelle

Research nerd.šŸ”¬Lover of animals. MPH/MHS. Share joy and kindness.ā˜®ļøBlessed to learn from brightest minds in cancer šŸ™šŸ». End disparitiesšŸŒŽ āœŒļøTweets=MešŸ¦€

ID: 1505118614940270592

calendar_today19-03-2022 09:47:06

286 Tweet

131 Followers

874 Following

FDA Oncology (@fdaoncology) 's Twitter Profile Photo

Today, FDA approved Enhertu (fam-trastuzumab deruxtecan-nxki) for unresectable or metastatic HER2-low breast cancer, a newly defined subset of HER2-negative breast cancer. This is the first drug approved to treat this subtype. thread 1/3 #bcsm fda.gov/news-events/pr…

chadi nabhan MD, MBA, FACP (@chadinabhan) 's Twitter Profile Photo

This Tue morning 8/9, U can’t miss #HealthcareUnfiltered with ⁦David Steensma, MD⁩ & ⁦Ross Levine⁩ discussing career paths for physicians: Academia/research vs. industry. Pros and cons. We also have a surprise guest mentored by Ross. Here’s a clip. Must listen/watch.

Michelle Wardzinski - Associate Director Biotech (@wardzi2michelle) 's Twitter Profile Photo

If everything could ever be this real forever If anything could ever be this good again The only thing I'll ever ask of you You've got to promise not to stop when I say when She sang

Rutgers Cancer Institute (@rutgerscancer) 's Twitter Profile Photo

.Rutgers Cancer Institute & RWJBarnabas are delighted to announce the appointment of Dr. Matthew Matasar as Chief of Blood Disorders at NJ’s leading #cancer center. When he arrives this fall from Memorial Sloan Kettering Cancer Center, Dr. Matasar will lead the growth of our #BMT & cellular therapy programs.

.<a href="/RutgersCancer/">Rutgers Cancer Institute</a> &amp; <a href="/RWJBarnabas/">RWJBarnabas</a> are delighted to announce the appointment of Dr. Matthew Matasar as Chief of Blood Disorders at NJ’s leading #cancer center. When he arrives this fall from <a href="/MSKCancerCenter/">Memorial Sloan Kettering Cancer Center</a>, Dr. Matasar will lead the growth of our #BMT &amp; cellular therapy programs.
Dr.Muna Al-Khaifi MD.CCFP.MPH (@munasaid44) 's Twitter Profile Photo

Fact 4: Women with BRCA1 mutation šŸ“ŒCancer Risk ā—¦ 40-70% Breast (vs 12%) ā—¦ 20-40% Ovarian (vs 1.5%) šŸ“ŒSurveillance : ā—¦ Breast MRI/mammogram @ 30 yr ā—¦ CA-125 and US not offered

Dr. Patt (@dapattmd) 's Twitter Profile Photo

Excited to testify about delays and barriers to care in Texas as we work with legislators to formulate solutions. ⁦Texas Oncology⁩ ⁦The US Oncology Network⁩ ⁦Community Oncology⁩ ⁦ASCO⁩

Excited to testify about delays and barriers to care in Texas as we work with legislators to formulate solutions. ⁦<a href="/TexasOncology/">Texas Oncology</a>⁩ ⁦<a href="/TheUSONetwork/">The US Oncology Network</a>⁩ ⁦<a href="/oncologyCOA/">Community Oncology</a>⁩ ⁦<a href="/ASCO/">ASCO</a>⁩
Motivational Quotes (@ezuiequotes) 's Twitter Profile Photo

"One of the best days in a person’s life is when you stop caring what everyone thinks about you, and you start caring about being yourself."

Paolo Tarantino (@ptarantinomd) 's Twitter Profile Photo

2022 will be remembered in breast oncology as the year of #ADCs. Relevant questions remain however to be answered, great opportunities lay ahead. Glad to share this interview by Clinical Adv in Hematology & Oncology. Thanks to Hope Rugo for the invitation! hematologyandoncology.net/archives/decem…

2022 will be remembered in breast oncology as the year of #ADCs. Relevant questions remain however to be answered, great opportunities lay ahead. Glad to share this interview by Clinical Adv in Hematology &amp; Oncology. Thanks to <a href="/hoperugo/">Hope Rugo</a> for the invitation!
hematologyandoncology.net/archives/decem…